Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP AIKAWA, Nadia E. FMUSP-HC
ROSA, Daniela T. A.
SAAD, Carla Goncalves FMUSP-HC
BONFA, Eloisa FMUSP-HC 2016
dc.identifier.citation REVISTA BRASILEIRA DE REUMATOLOGIA, v.56, n.6, p.478-482, 2016
dc.identifier.issn 0482-5004
dc.description.abstract Objective: To evaluate the prevalence of systemic and localized infection by Candida species and its possible association with demographic, clinical and laboratory manifestations and therapy in patients with rheumatic diseases taking TNF blockers. Methods: Consecutive patients with rheumatic diseases receiving anti-TNF agents were included. The following risk factors up to four weeks prior to the study were analyzed: use of antibiotics, immunosuppressant drugs, hospitalization and invasive procedures. All subjects were evaluated for clinical complaints; specific blood cultures were obtained for fungi and blood samples were collected for Candida spp. detection by polymerase chain reaction. Results: 194 patients [67 with rheumatoid arthritis (RA), 47 with ankylosing spondylitis (AS), 36 with juvenile idiopathic arthritis (JIA), 28 with psoriatic arthritis and 16 with other conditions] were included. The average age of patients was 42 +/- 16 years, with 68 (35%) male and mean disease duration of 15 +/- 10 years. Sixty-four (33%) patients were receiving adalimumab, 59 (30%) etanercept and 71 (36%) infliximab. Eighty-one percent of patients were concomitantly taking immunosuppressant drugs. At the time of the study, only one (0.5%) patient had localized fungal infection (vaginal candidiasis). None of the patients included had systemic candidiasis with positive blood cultures for fungi or IDCR positive for Candida spp. in peripheral blood sample. Conclusions: This was the first study to assess the prevalence of invasive and localized fungal disease by Candida in a significant number of patients with rheumatic diseases on anti-TNF therapy, and demonstrated low risk of candidiasis, despite the high prevalence of immunosuppressive drug use. (C) 2015 Elsevier Editora Ltda.
dc.description.sponsorship · Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/51897-5]
· Conselho Nacional do Desenvolvimento Cientifico e Tecnologico (CNPq) [302724/2011-7, 301411/2009-3]
· Federico Foundation for CAS
· Nucleo de Apoio a Pesquisa ""Saude da Crianca e do Adolescente"", USP (NAP-CriAd)
dc.language.iso eng
dc.language.iso por
dc.relation.ispartof Revista Brasileira de Reumatologia
dc.rights openAccess
dc.subject Systemic candidiasis; Candida spp.; Anti-TNF; Rheumatoid arthritis; Ankylosing spondylitis
dc.subject.other necrosis-factor-alpha; polymerase chain-reaction; fungal-infections; arthritis; albicans; classification; infliximab; criteria; blood; risk
dc.title Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy
dc.title.alternative Infecção sistêmica e localizada por Candida spp. em pacientes reumatológicos em terapia anti-TNF
dc.type article
dc.rights.holder Copyright ELSEVIER SCIENCE INC LIM/53 LIM/17 LIM/36
dc.identifier.doi 10.1016/j.rbre.2015.08.004
dc.identifier.pmid 27914593
dc.type.category original article
dc.type.version publishedVersion AIKAWA, Nadia E.:HC:ICHC NEGRO, Gilda M. B. Del:HC:LIM/53 MORAES, Julio C. B.:HC:ICHC RIBEIRO, Ana C. M.:HC:ICHC SAAD, Carla Goncalves:HC:ICHC SILVA, Clovis A.:FM:MPE BONFA, Eloisa:FM:MCM · ROSA, Daniela T. A.:Univ Sao Paulo, Fac Med, Lab Micol Med LIM 53, Sao Paulo, SP, Brazil; Inst Med Trop Sao Paulo, Sao Paulo, SP, Brazil 2-s2.0-85007368640 WOS:000389548800003 SCIELO:S0482-50042016000600478 NEW YORK USA
hcfmusp.relation.reference · ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
· Ashman RB, 2008, FRONT BIOSCI, V13, P3334
· Asmundsdottir LR, 2002, J CLIN MICROBIOL, V40, P3489, DOI 10.1128/JCM.40.9.3489-3492.2002
· Bennett PH, 1968, POPULATION STUDIES R, P456
· CHRYSSANTHOU E, 1994, SCAND J INFECT DIS, V26, P479, DOI 10.3109/00365549409008623
· DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003
· Ellerin T, 2003, ARTHRITIS RHEUM, V48, P3013, DOI 10.1002/art.11301
· Filler SG, 2005, CLIN INFECT DIS, V41, pS208, DOI 10.1086/430000
· GARRETT S, 1994, J RHEUMATOL, V21, P2286
· Gudlaugsson O, 2003, CLIN INFECT DIS, V37, P1172, DOI 10.1086/378745
· KAN VL, 1993, J INFECT DIS, V168, P779
· Loffler J, 1997, J CLIN MICROBIOL, V35, P3311
· LOUIE A, 1994, INFECT IMMUN, V62, P2761
· Miyamoto H, 2012, MOD RHEUMATOL, V22, P903, DOI 10.1007/s10165-012-0594-0
· Petty RE, 2004, J RHEUMATOL, V31, P390
· PIZZO PA, 1990, SEMIN ONCOL, V17, P6
· PONTON J, 1986, INFECT IMMUN, V53, P565
· PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
· Richardson Malcolm, 2009, Front Biosci (Schol Ed), V1, P246
· Rychly DJ, 2005, PHARMACOTHERAPY, V25, P1181, DOI 10.1592/phco.2005.25.9.1181
· Senet Jean-Marcel, 1997, Revista Iberoamericana de Micologia, V14, P6
· Springer J, 2012, JCR-J CLIN RHEUMATOL, V18, P52, DOI 10.1097/RHU.0b013e31823ed485
· Tsiodras S, 2008, MAYO CLIN PROC, V83, P181
· Van Burik JA, 1998, J CLIN MICROBIOL, V36, P1169
· van Dartel SAA, 2013, ANN RHEUM DIS, V72, P895, DOI 10.1136/annrheumdis-2012-201338
· Zaoutis TE, 2004, PEDIATR INFECT DIS J, V23, P635, DOI 10.1097/01.inf.0000128781.77600.6f
dc.description.index MEDLINE
hcfmusp.citation.scopus 6
hcfmusp.citation.wos 5 Brasil

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account